Fulcrum Therapeutics, Inc.FULCNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank29
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P29
Within normal range
vs 3Y Ago
-0.6x
Contraction
Streak
4 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-18.75%
Q3 2025-2.84%
Q2 20258.99%
Q1 202510.21%
Q4 202410.99%
Q3 2024-132.41%
Q2 2024332.69%
Q1 2024-8.94%
Q4 2023-1.15%
Q3 2023-9.49%
Q2 202313.62%
Q1 2023-22.59%
Q4 202229.66%
Q3 20221.81%
Q2 2022-28.33%
Q1 20220.11%
Q4 20212.45%
Q3 2021-24.77%
Q2 2021-11.51%
Q1 202118.77%
Q4 2020-341.55%
Q3 202067.92%
Q2 20209.13%
Q1 2020-242.62%
Q4 201965.21%
Q3 2019-7.61%
Q2 2019-20.46%
Q1 2019-3.42%
Q4 2018-95.58%
Q3 201845.23%
Q2 2018-24.25%
Q1 20180.00%